Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Mol Cancer Res. 2017 Jan 10;15(3):269–280. doi: 10.1158/1541-7786.MCR-16-0227-T

Figure 6. Heterozygosity for P242R confers resistance to cisplatin in population-derived cells.

Figure 6

Human lymphoblastoid cells derived from individuals with the genotype P/P (WT) or P/R (heterozygous for P242R) at residue 242 were plated at a density of 20,000 cells/well in a 96 well plate. Cells were treated with various concentrations (0-12.5 μM) of cisplatin for 24 h and cell viability was measured using CellTiter-Glo®. Data are presented as mean ± SEM of the percent viability (n = 3).